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Back Talk:  
The Medicine Cabinet 
 
Dane Shiltz, PharmD, BCPS 
Inpatient Family Medicine 
Methodist Hospital 
 
November 12, 2011 
Disclosure 
• None 
Objectives 
• Differentiate between traditional therapies for 
back pain of nociceptive origin 
 
• Discuss the debate regarding long-term opioid 
use & its impact on psychosocial functioning 
 
• Differentiate between neuropathic back pain 
agents 
General Back Pain Details 
• Lifetime incidence ~50-80% 
 
 
• Peak onset ages 30-40 
 
 
• Direct US medical costs $12.2-90.6 BILLION/yr 
 
 
• Lost productivity & disability compensation 
 
 
• Frequently associated with depression or anxiety 
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Chou. Drugs. 2010;70:387-402. 
Schnitzer, et al. J Pain Symptom Manage. 2004;28:72-95. 
Definition & Classification 
• Low back pain (LBP): pain localized to lumbar 
area between inferior ribcage & waistline 
– May include sciatica, with pain radiating down to 
posterior-lateral thigh distal to the knee 
 Classification Duration 
Acute <6 weeks 
Subacute 6-12 weeks 
Chronic >12 weeks 
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Chou. Drugs. 2010;70:387-402. 
Schnitzer, et al. J Pain Symptom Manage. 2004;28:72-95. 
4 Main Classes of Low Back Pain 
Non-
specific 
Mechanical Visceral / 
referred 
Non-
mechanical 
Prevalence 70% 27% 2% 1% 
Attributed 
Conditions 
• Lumbar  
  sprain 
 
• Lumbar  
  strain 
 
• No  
  identifiable  
  origin 
• Degenerative  
  disc disease 
 
• Herniated  
  disc 
 
• Osteoporotic  
  compression  
  fracture* 
 
• Spinal  
  stenosis 
• Aortic  
  aneurysm 
 
• Pelvic organ  
  disease 
 
• GI disease 
  
• Renal  
  disease* 
 
• Cancer 
 
• Infection* 
 
•Inflammatory 
  arthritis 
 
• Paget  
  disease of  
  bone 
Chronic LBP: A Mixed Pain Syndrome 
• Nociceptive pain component (nonspecific pain) 
– Inflammatory response from tissue injury 
– Dull, aching, or throbbing pain 
– Usually adaptive & temporary once injury heals 
 
 
• Neuropathic pain component (mechanical pain) 
– Lesion or disease affecting somatosensory system 
– Originates from lumbar spine and/or nerve roots 
– Paroxysmal, dysaesthetic and/or thermal 
Acute nociceptive pain 
Chronic nociceptive 
& neuropathic pain →  
LBP Treatment Goals 
• Effectively reduce, if not resolve, pain 
– Fewest interventions (meds) necessary 
– Shortest duration at lowest dose 
– Most cost-effective 
• Prevent and/or minimize treatment-related 
side effects 
– Avoid drug-drug & drug-disease interactions 
• Restore physical functioning 
• Decrease disease burden on patient & society 
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Schnitzer, et al. J Pain Symptom Manage. 2004;28:72-95. 
Factors Influencing Nonspecific LBP 
Pharmacologic Treatment Choice 
• Symptom duration – acute vs. chronic 
• Symptom intensity & quality 
• Evidence 
• Prior response to medications 
• Adverse effect profile 
• Drug-drug & drug-disease interactions 
• Cost 
• Convenience - # doses/day 
Chou. Drugs. 2010;70:387-402. 
Methodological Limitations 
Most studies of only moderate quality 
– Limited description of randomization & blinding 
– Few active comparisons; most placebo only 
– Small sample size  
– Safety reporting limited & vague 
– Short study duration & insufficient follow-up period 
– Variation in pain assessment & efficacy criteria 
– Multiple pain assessment scales used 
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Chou. Drugs. 2010;70:387-402. 
Schnitzer, et al. J Pain Symptom Manage. 2004;28:72-95. 
Treatment Pearls 
• 2/3 cases resolve within 6 weeks of onset 
• LBP >12 weeks = ↓ likelihood for improvement 
• Medication does not alter natural course 
– Meds target symptoms & functional status  
• Best evidence for acute, short-term use 
• Use shortest duration necessary, stop when no 
longer pain relief 
• Chronic LBP does not mandate long-acting meds  
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Chou. Drugs. 2010;70:387-402. 
Schnitzer, et al. J Pain Symptom Manage. 2004;28:72-95. 
Traditional Back Pain Options 
• Acetaminophen (APAP) 
 
• Nonsteroidal anti-inflammatory drugs (NSAIDs) 
 
• Corticosteroids 
 
• Muscle relaxants 
 
• Tramadol 
 
• Opioids 
 Indications 
 Efficacy 
 Place in therapy 
 Side effects, contraindications 
 Monitoring 
Acetaminophen (APAP) 
• 1st line agent for acute & chronic LBP 
 
• May be equivalent NSAIDs for acute back pain 
– Possibly inferior for chronic back pain 
– Ineffective for neuropathic pain 
• Max 4 grams in 24 hours 
– 1000mg 4x/day, up to 28 days studied 
– Educate patients on APAP-containing meds! 
• Caution use in alcohol users 
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Schnitzer, et al. J Pain Symptom Manage. 2004;28:72-95. 
Davies, et al. Eur Spine J. 2008;17:1423-1430. 
Chou, et al. Ann Intern Med. 2007;147:505-514. 
NSAIDs 
• 1st line agent for acute & chronic LBP 
• Superior vs. placebo 
– Strongest evidence for acute pain 
– Better data for chronic pain vs. APAP 
– Ineffective for neuropathic pain 
 
• No agent superior    NSAIDs ≈ celecoxib 
• Toxicities limit more prevalent use 
– Studies not designed to assess GI & CV outcomes 
– Avoid in age >75, GI/CV disease history 
Schnitzer, et al. J Pain Symptom Manage. 2004;28:72-95. 
Davies, et al. Eur Spine J. 2008;17:1423-1430 
Chou, et al. Ann Intern Med. 2007;147:505-514. 
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Chou. Drugs. 2010;70:387-402. 
Morlion B. Curr Med Res Opin. 2011;27:11-33. 
 NSAID & Dose Duration 
(days) 
LBP Type 
Ibuprofen 400mg TID 2, 7 Acute 
Ibuprofen 600mg TID 10 Acute 
Ibuprofen 800mg TID 7 Acute 
Naproxen 250mg TID 42 Acute 
Naproxen 250mg 3-4x/day 15 Acute 
Naproxen 250mg 4x/day 14 Acute 
Naproxen 550mg BID 14 Chronic 
Diflunisal 500mg BID 7-15 Acute 
Diflunisal 500mg BID 14, 28 Chronic 
NSAID Toxicities 
• Gastrointestinal 
– Dyspepsia (~30-40%) 
– Gastroduodenal 
ulceration 1-2 
cases/1,000 
patients/year 
 
 
• Cardiovascular 
– Concurrent aspirin 
– ASA doses <150mg/day 
Risk for ulcer on NSAIDs 
– Age >60 
– H/o peptic ulcer disease 
– Multiple NSAIDs 
– High-dose NSAIDs 
– Long-term use 
– Concurrent 
corticosteroids 
 
Lichtenstein DR.. Arthritis  Rheum. 1995;38:5-18. 
Henry D, et al. Gastroenterology. 1993;105:1078-1088. 
Ruoff G. Am J Med. 1998;105:53S-60S. 
NSAIDs & Nephrotoxicity 
 
• ↓ Renal blood flow 
• ↑ Na+, H20 retention 
 
• Caution use with ARB’s,  
ACE inhibitors, and/or 
diuretics! 
– Elderly, CKD susceptible 
– Monitor Cr, K in 1-2 weeks 
 
• Caution CKD, HTN, heart 
failure, cirrhosis 
 Ruoff G. Am J Med. 1998;105:53S-60S. 
Corticosteroids 
• Epidural injections for radiculopathy (sciatica) 
– Benefit minimal, variable & only short-term 
– IM, IV methylprednisolone 160mg, 500mg x 1 
• No benefit for any corticosteroid vs. placebo 
via any route for acute or chronic LBP 
• Adverse events poorly described 
– Rare injection site infection risk 
• Not recommended for acute or chronic LBP 
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Chou, et al. Ann Intern Med. 2007;147:505-514. 
Staal JB. Cochrane Database of Systemic Reviews. 2008. 
Johnson M, et al. J Fam Pract. 2011;60:297-298 
Staal JB, et al. Spine. 2008;34:49-59. 
Deyo RA, et al. J Am Board Fam Med. 2009;22:62-68. 
Muscle Relaxants (MRs) 
• Superior to placebo for acute LBP 
 
• 2nd line or adjunct option due to side effects 
– Short courses (2-7, max 14 days) recommended 
– Tizanidine + APAP/NSAID = better pain relief  
 
• No single MR superior or best tolerated 
 
• Not recommended for chronic LBP 
– Limited evidence, sedation, dizziness, dependence 
– No benefit for neuropathic pain (sciatica) 
Duffy RL. Prim Care Clin Office Pract. 2010;37:729-741. 
Chou, et al. Ann Intern Med. 2007;147:505-514. 
van Tulder MW, et al. Cochrane Database Syst Rev. 2008:CD004254. 
See S, et al. Am Fam Physician. 2008;78:365-370. 
Chou R. Drugs. 2010;70:387-402. 
Variation in Selecting a MR 
• Tizanidine (Zanaflex®) 2-4mg q6-8h 
– Dose-dependent hypotension, dry mouth, sedation 
– Monitor LFTs at baseline, 1 month, 3 months 
 
• Cyclobenzaprine (Flexeril®) 5-10mg TID 
– Anticholinergic 
– 5mg=10mg, but less sedation 
 
• Carisoprodol (Soma®) – avoid use! 
– Physical or psychological dependence possible 
See S, et al. Am Fam Physician. 2008;78:365-370. 
Chou R. Drugs. 2010;70:387-402. 
Tramadol (± APAP) 
• Combination with APAP provides synergy 
– Lower doses, longer duration, better pain relief 
• Caution SSRI, SNRI drugs 
• No evidence in acute LBP 
• 2nd line agent for moderate-severe chronic LBP 
– Benefits similar to NSAIDs, weak opioids 
– Abuse & withdrawal potential 
– Potential benefit in nociceptive & neuropathic LBP 
Barkin RL. Am J Ther. 2001;8:433-442. 
Duffy RL. Prim Care Clin Office Pract. 2010;37:729-741. 
Ruoff GE. Clin Ther. 2003;25:1123-1141. 
Chou R. Drugs. 2010;70:387-402. 
Tramadol + APAP Literature 
• Tramadol 37.5mg TID – 75mg 4x/day + APAP x 12 
weeks vs. placebo in moderate chronic LBP 
– Moderate improvement in chronic LBP 
– Minimal improvement in functional status 
 
• Side effects: nausea (~13%), sedation (~12%), 
constipation (~11%) generally less vs. opioids 
 
• Promising results, yet little data >12 weeks  
Peloso PM, et al. J Rheumatol. 2004;31:2454-63. 
Ruoff GE, et al. Clin Ther. 2003;23:1123-1141. 
Schnitzer TJ, et al. J Rheumatol. 2000;27:772-778. 
Opioids for Acute LBP 
• Potent, short-term pain relief vs. placebo 
• May be no better vs. NSAIDs or SMRs 
• No specific opioid superior 
• Effective for nociceptive & neuropathic pain 
• 2nd or 3rd line for severe, disabling acute pain not 
controlled/not likely to respond to APAP/NSAIDs 
– Alternative for high risk of NSAID-induced toxicity 
– Screen for substance abuse prior to initiation 
– Time-limited course (1 month) to determine response 
 Duffy RL. Prim Care Clin Office Pract. 2010;37:729-741. 
Kuijpers T, et al. Eur Spine J. 2011;20:40-50. 
Chou, et al. Ann Intern Med. 2007;147:505-514. 
Schnitzer, et al. J Pain Symptom Manage. 2004;28:72-95. 
Palangio, et al. Clin Ther. 2002;24:87-98. 
Chou R. Ann Intern Med. 2007;147:478-491. 
Dose-Dependent Side Effects 
Complaint Incidence Comments 
Constipation** 20-40% Prophylactic bowel regimen 
N/V 30% Resolves days-weeks 
Sedation 30% Usually decreases with time 
Dry mouth 25% Caution dental carries 
Dizziness 14% Risk for falls, caution elderly 
Pruritis 13% Antihistamines? 
Hypogonadism ?? Monitor fatigue, libido  
Barkin RL. Am J Ther. 2001;8:433-442. 
Kalso E, et al. Pain. 2004;112:372-380. 
Colameco S, et al. J Am Osteopath Assoc. 2009;109:20-25. 
Morlion B. Curr Med Res Opin. 2011;27:11-33. 
Chou R, et al. J Pain. 2009;10:113-130. 
Jamison RN. Spine. 1998;23:2591-2600. 
Chronic Opioid Debate in LBP 
• Limited quality data for long-term effectiveness 
– Reduce pain VAS score ~30% vs. placebo 
– Opioid naïve & experienced with moderate-severe pain 
• Initially improve pain, but long-term pain relief 
unproven combined with known side effects 
– Mood improvement ≠ pain improvement 
• Do not improve activity or facilitate return to work! 
• Generally not appropriate for chronic LBP 
– Requires monitoring of benefit, side effects & misuse 
Duffy RL. Prim Care Clin Office Pract. 2010;37:729-741. 
Kuijpers T, et al. Eur Spine J. 2011;20:40-50. 
Chou, et al. Ann Intern Med. 2007;147:505-514. 
Grady D, et al. Arch Intern Med. 2011;E1-E2. 
Kalso E, et al. Pain. 2004;112:372-380. 
Deshpande A, et al. Cochrane Database Syst Rev. 2007;18:CD004959. 
Long-Term Use: What Formulation? 
• Chronic LBP ≠ continuous 24/7, unrelenting pain 
• More consistent opioid exposure may reduce 
euphoric effects & reduce abuse potential 
• No evidence long-acting formulations are more 
effective vs. short-acting or PRN doses 
– Continuous exposure may facilitate tolerance 
– Tolerance  dose escalations  endocrine problems 
• No reason to switch to long-acting opioids if 
doing well on a short-acting, PRN regimen 
Chou R. Drugs. 2010;70:387-402. 
Serious Concerns for Opioids 
• Analgesic tolerance 
– increasing doses to attain same pain relief 
– vs. disease progression vs. addiction vs. diversion 
• Abuse, misuse, addiction, diversion - INSPECT 
– major depression, psychiatric conditions: more 
likely to initiate, abuse & not respond to opioids  
• Physical dependence 
• Overdose – incidence on the rise 
– dose-related, formulation-dependent 
– depression, substance abuse, benzodiazepines 
Grady D, et al. Arch Intern Med. 2011;E1-E2. Deyo RA, et al. J Am Board Fam Med. 2009;22:62-68. 
Opioids & Psychosocial Functioning 
• Opioids do not improve functional status or 
facilitate return to work 
• Duration >7 days, ↑ dose, >1 prescription within 
6 weeks of acute back injury associated with 
notable increase in work disability at 1 year 
• Opioids may: 
– impair cognition 
– contribute to poor treatment outcomes 
– foster reliance on the healthcare system 
Jamison RN. Spine. 1998;23:2591-2600. 
Franklin GM. Spine. 2008;33:199-204. 
Moore JE. Phys Med Rehabil Clin N Am. 2010;21:801-815. 
Opioids & Addiction in Chronic LBP 
• Most trials not designed to assess 
• Few use a validated detection tool 
• Poor quality trials used to define prevalence 
• Current prevalence estimate of aberrant opioid- 
related behavior in chronic back pain: 5-24% 
• Possible predictors for addiction 
– Additional comorbidities      -- Younger age 
– Other substance abuse disorders    -- Female 
Martell BA. Ann Intern Med. 2007;146:116-127. 
Methadone 
• Less potential for abuse 
• Long, variable half-life 15-60 hours 
– Not used for PRN or breakthrough pain 
• No active metabolites 
 
• Variable pharmacokinetics & pharmacodynamics 
• High risk for side effects – start low, go slow! 
• QTc interval prolongation & arrhythmias 
– Dose-related, concomitant drugs, drug  interactions 
 Chou R, et al . J Pain. 2009;10:113-130. Grady D, et al. Arch Intern Med. 2011;E1-E2. 
My Patient is on Chronic Opioids…. 
• Evaluate pain, functional status & side effects regularly 
 
• No max dose, but total doses >200mg/day morphine 
equivalent should permit evaluation of effectiveness 
– Switch to another opioid at reduced dose 
– Taper & discontinue opioid therapy altogether 
– Consider pain specialist referral 
 
• Reemphasize opioid use as a therapeutic trial run 
 
• Lack of alternatives not reason to continue unproven & 
unsafe chronic opioids when no clear end point exists 
Chou R, et al . J Pain. 2009;10:113-130. 
Grady D, et al. Arch Intern Med. 2011;E1-E2. 
Neuropathic Back Pain Options 
• Tricyclic antidepressants (TCAs) 
 
• Duloxetine (Cymbalta®) 
 
• Gabapentin (Neurontin®) 
 
• Pregabalin (Lyrica®) 
 
 
• Opioids 
TCAs – Nortriptyline, Desipramine 
• Target neuropathic component of LBP 
• Analgesia independent of antidepressant actions 
• TCAs might be more effective vs. placebo for 
chronic pain; no data in acute LBP 
– Mild reduction in pain 
– No benefit on functional impairment, ADL 
• Side effects: S.L.U.D.G.E. , sedation, weight gain 
• 2nd/3rd line agent for chronic LBP after 
insufficient relief to other agents  
Duffy. Prim Care Clin Office Pract. 2010;37:729-741. 
Morlion B. Curr Med Res Opin. 2011;27:11-33. 
Chou, et al. Ann Intern Med. 2007;147:505-514. 
Kuijpers T, et al. Eur Spine J. 2011;20:40-50. 
TCA Prescribing Considerations 
• Undiagnosed depression 
• Body mass 
• Social drug use history & abuse potential 
• Baseline cardiac arrhythmias 
• Seizure history 
• Elderly comorbidities 
– BPH, diabetes, constipation, dementia 
– Beer’s Criteria 
• Existing medications – tramadol, opioids 
Duloxetine 
• Quality & overall favorable data for reducing 
chronic LBP vs. placebo 
• Maintained benefit up to 41 weeks duration 
• Duloxetine 60mg daily 
– Usually start at 30mg, then increase after 1 week 
– Fewer side effects (nausea, dry mouth) vs. 120mg 
• Reliable option for chronic LBP 
– Also useful if underlying depression 
Skljarevski V. J Pain. 2010;11:1282-1290. 
Skljarevski V. Pain Med. 2010;11:648-657. 
Morlion B. Curr Med Res Opin. 2011;27:11-33. 
Skljarevski V. Eur J Neurol. 2009;16:1041-1048. 
Gabapentin 
• Limited data specifically in chronic back pain 
• Reduced pain, increased walking distance in 
lumbar spinal stenosis, lumbar disc hernia vs. 
placebo 
• TID dosing titrated to target 2400mg/day 
• Well tolerated 
– Mild, transient sedation, dizziness 
• Well-tolerated option with possible benefit in 
neuropathic chronic back pain 
Duffy RL. Prim Care Clin Office Pract. 2010;37:729-741. 
Yaksi A. Spine. 2007;32:939-942. 
Kasimcan O. Neurol Med Chir (Tokyo). 2010;50:1070-1073. 
Pregabalin 
• No more effective as monotherapy vs. placebo  
for chronic LBP 
• No benefit for refractory neuropathic chronic  
back pain due to spinal stenosis or radiculopathy 
 
• Not proven useful as monotherapy for chronic LBP 
Romano CL. J Orthopaed Traumatol. 2009;10:185-191. 
Morlion B. Curr Med Res Opin. 2011;27:11-33. 
Acute LBP Treatment Algorithm 
Acetaminophen (APAP) 
NSAID 
therapy 
Muscle 
Relaxant 
Opioids 
MILD 
SEVERE 
± 
± 
Chronic LBP Treatment Algorithm 
Acetaminophen (APAP) 
NSAID Tramadol 
Opioids 
MILD 
SEVERE 
Evaluate use for duloxetine, 
gabapentin, or TCAs at any severity 
Take Home Points 
• Screen for depression 
• Determine potential for neuropathic pain involvement 
– Assess not only pain intensity, but also pain quality 
• Individualize treatment decisions 
– Caution polypharmacy in the elderly 
• Meds may reduce pain; little effect on functional status 
• Opioids – clear evidence for harm; ?? long-term benefit 
• False perceptions & expectations about opioid use drive 
patient requests for chronic opioids when risk > benefit 
• Never overlook non-pharmacologic approaches 
• Active comparator, combination therapy , topical & long-
term quality safety/efficacy studies desperately needed 
Questions 
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